10.12.2015 Views

Non-Alcoholic Steatohepatitis Pipeline Review Market Size, Share, Growth & Trend to 2015 Radiant Insights, Inc

Summary Radiant Insights's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-alcoholic-steatohepatitis-pipeline-review-h2-2015 investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Summary

Radiant Insights's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings,

Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-alcoholic-steatohepatitis-pipeline-review-h2-2015

investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Small Molecule <strong>to</strong> Inhibit SCD-1 for <strong>Non</strong>alcoholic <strong>Stea<strong>to</strong>hepatitis</strong> - Drug Profile 175<br />

Small Molecules <strong>to</strong> Activate AMPK for Fatty Liver Disease - Drug Profile 176<br />

Small Molecules <strong>to</strong> Agonize Farnesoid X Recep<strong>to</strong>r for <strong>Non</strong>-alcoholic <strong>Stea<strong>to</strong>hepatitis</strong> and Primary<br />

Biliary Cirrhosis - Drug Profile 177<br />

solithromycin - Drug Profile 178<br />

SR-9238 - Drug Profile 180<br />

STNM-09 - Drug Profile 181<br />

TGFTX-3 Program - Drug Profile 182<br />

tipelukast - Drug Profile 183<br />

TRX-318 - Drug Profile 185<br />

VB-201 - Drug Profile 186<br />

VBY-376 - Drug Profile 188<br />

VK-0214 - Drug Profile 189<br />

Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-alcoholicstea<strong>to</strong>hepatitis-pipeline-review-h2-<strong>2015</strong><br />

VK-2809 - Drug Profile 190<br />

volixibat potassium - Drug Profile 192<br />

VVP-100-X - Drug Profile 193<br />

ZGN-839 - Drug Profile 194<br />

<strong>Non</strong>-<strong>Alcoholic</strong> <strong>Stea<strong>to</strong>hepatitis</strong> - Recent <strong>Pipeline</strong> Updates 195<br />

<strong>Non</strong>-<strong>Alcoholic</strong> <strong>Stea<strong>to</strong>hepatitis</strong> - Dormant Projects 268<br />

<strong>Non</strong>-<strong>Alcoholic</strong> <strong>Stea<strong>to</strong>hepatitis</strong> - Discontinued Products 270<br />

<strong>Non</strong>-<strong>Alcoholic</strong> <strong>Stea<strong>to</strong>hepatitis</strong> - Product Development Miles<strong>to</strong>nes 271<br />

Featured News & Press Releases 271<br />

Appendix 278<br />

Methodology 278<br />

Coverage 278<br />

Secondary Research 278<br />

Primary Research 278

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!